Biodexa Pharmaceuticals (NASDAQ:BDRX) Downgraded by Wall Street Zen to “Sell”

Biodexa Pharmaceuticals (NASDAQ:BDRX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Monday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

BDRX opened at $0.65 on Monday. Biodexa Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $19.30. The stock’s 50 day simple moving average is $1.25 and its 200-day simple moving average is $3.89.

Biodexa Pharmaceuticals shares are scheduled to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last posted its quarterly earnings results on Friday, March 27th. The company reported $0.70 earnings per share for the quarter. As a group, equities analysts expect that Biodexa Pharmaceuticals will post -1.25 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals comprises 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th largest holding. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals at the end of the most recent quarter. 17.51% of the stock is currently owned by institutional investors and hedge funds.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.